

# MammaPrint Can Help Uncover Your Tumor's Hidden Biology



**MammaPrint**, when performed on your tumor, can help answer many of your questions.

*What are my treatment options?*

*What's the likelihood that my cancer will recur?*

*Should I consider chemotherapy?*



22 Morgan, Irvine, CA 92618, (888) 321-2732 www.agendia.com © 2014

USA-008-V6

You have just been diagnosed with breast cancer...

Now What?



What If I Don't Need Chemotherapy?

## Every tumor is different... Why should they all be treated the same?

When you first hear that you have breast cancer, many questions may pop into your head:

- Will my cancer recur?
- Will I need chemotherapy?
- What treatment gives me the best chance at beating this?

These are appropriate questions that you may be asking your doctor. With advancements in cancer medicine, there are **genomic** tests today that can help answer these questions by uncovering more about your tumor's biology. These tests help identify your specific tumor type, the likelihood of its recurrence, and how it may respond to various treatments.

## What is genomic testing?

Genomic tests look at your specific tumor's genes, to help find out what's driving its growth. Using gene expression testing to help design a tailored treatment plan is called **personalized medicine**. These are not the same as **genetic** tests that determine your inherited risk or hereditary predisposition for cancer.

Your physician will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer. These factors, along with your tumor's **genomic profile**, can help you and your physician make the most informed treatment decisions for your specific type of cancer.

## How do I get a personalized genomic test done on my tumor?

Ask your doctor to run **MammaPrint** testing on your breast cancer. This test can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage. No new biopsy or surgical tissue sample is typically required.

## What information will the MammaPrint test result show?

MammaPrint is a 70-gene test that will assess your cancer's risk of recurrence, or how likely the cancer is to return in the future. You are given definitive results, either a Low Risk or High Risk result, with no intermediate or undetermined results. A Low Risk result means you have a 10%, or 1 in 10 chance of your cancer returning. A High Risk result means you have a 29%, or 3 out of 10 chance of it returning. These results are based on a 10-year follow-up of a reference group of patients who had no additional treatment.<sup>1</sup> A Low Risk result doesn't guarantee that your cancer will not recur, and a High Risk result doesn't guarantee that your cancer will. These results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions.



## What if I am in the High Risk group?

If you are in the High Risk group, the addition of chemotherapy may be considered as part of your treatment plan.

## What if I am in the Low Risk group?

If you are in the Low Risk group, you have a lower chance of the cancer returning, and there is little, if any, benefit to getting chemotherapy. Studies have shown that the addition of hormone therapy alone for ER-positive breast cancer can lower the risk of recurrence by up to 50%.<sup>2</sup>

## Why should I use MammaPrint?

MammaPrint provides you and your doctor deeper insight into tumor pathways, uncovering your hidden tumor biology. It gives a clearer picture of how your breast cancer is functioning, leading to more informed treatment decision making. MammaPrint is the first FDA-cleared breast cancer recurrence assay, and is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data.<sup>3</sup>

1. Buyse M, et al. *J Nat Cancer Institute*. 92-1183;98:17;2006.  
2. American Cancer Society. "Tamoxifen and Raloxifene." *Cancer.org*, 17 July 2013. Web. 17 July 2014.  
3. Drukker CA, et al. *Int J Cancer*. 36-929;(4)133;2013.